In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Octagen Corp.

Executive Summary

Hemophiliac treatments with a specialization in blood coagulation cascade

You may also be interested in...



Reckitt Targets UK's Painful ‘Tweens’ With Double-Strength Nurofen

Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."

Novartis’s New Eye Treatment Beovu Gets CHMP Nod

Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.

Xellia and Kabi Broaden US Antibiotics Offering

Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV000593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel